Current Report Filing (8-k)
August 13 2021 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 13, 2021
POINT BIOPHARMA GLOBAL INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
001-39311
|
85-0800493
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
|
4850 West 78th Street,
Indianapolis, IN
|
46268
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
|
(647) 812-2417
Registrant’s telephone number, including
area code
(Former name or former address, if changed since
last report)
_______________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.0001 per share
|
PNT
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On August 13, 2021, POINT Biopharma Global Inc.
issued a press release announcing financial results for the quarter ended June 30, 2021. A copy of the press release is being furnished
as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Current Report
on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 13, 2021
|
POINT BIOPHARMA GLOBAL INC.
|
|
|
|
By:
|
/s/ Bill Demers
|
|
Name:
|
Bill Demers
|
|
Title:
|
Chief Financial Officer
|
Therapeutics Acquisition (NASDAQ:RACA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Therapeutics Acquisition (NASDAQ:RACA)
Historical Stock Chart
From Jul 2023 to Jul 2024